Metronome v. Bioserene: Cannabis Topical Patent Case Transferred on Filing Day
Metronome LLC filed an infringement action against Bioserene Inc. in the Southern District of Florida over US10653736B2, covering cannabis-derived botanical topical treatments. The case was administratively closed and renumbered the same day it was filed — a rare procedural misstep that immediately redirected the dispute to a new docket.
A cannabis topical patent suit reassigned before it could begin
On July 16, 2025, Metronome LLC filed a patent infringement action against Bioserene Inc. in the Southern District of Florida, asserting US10653736B2 — a patent directed at topical treatments incorporating cannabis sp. derived botanical drug products. The filing targeted Bioserene’s allegedly infringing activities in what is an increasingly active space for cannabis-based therapeutics IP enforcement.
The case never proceeded on the merits at the originally filed docket. The court’s clerk issued a notice the same day identifying that the filer had selected the wrong venue within the electronic filing system. The case was administratively closed under docket number 1:25-cv-23170 and renumbered as 25-cv-14255, where litigation is expected to continue. No substantive rulings, responsive pleadings, or judicial orders were entered on the original docket.
The immediate transfer suggests a clerical or system-level venue selection error by plaintiff’s counsel rather than a strategic choice of forum. The operative litigation now proceeds under the new case number, and the substantive dispute — including infringement allegations, any validity challenges, and potential damages — remains entirely unresolved. The public record on the original docket provides no information about the strength of the infringement claims or Bioserene’s likely defenses.
Filing to Case Terminated in 0 days
Case opened and transferred on the same calendar day — zero active litigation days recorded
Wrong venue filed: what the administrative transfer means for both parties
Administrative closure for wrong venue is not a dismissal
When a filer selects the wrong venue in a federal court’s electronic case management system, the clerk may administratively close the original docket and issue a new case number in the correct venue or division. This is a purely procedural correction — no merits ruling is made, no rights are adjudicated, and no statute of limitations consequences typically attach. The dispute continues under the renumbered docket.
Procedural transfer — no merits decidedMetronome’s infringement claims remain fully alive
The administrative renumbering does not prejudice Metronome LLC’s ability to pursue its patent infringement claims against Bioserene. The case continues as 25-cv-14255, and all original allegations under US10653736B2 carry forward. Plaintiff’s counsel at Beusse Sanks PLLC is expected to proceed with service and substantive filings on the new docket. No strategic rights were waived by the filing error.
Claims preserved — litigation continuesBioserene faces the same infringement exposure under the new docket
Bioserene Inc. faces an unchanged legal position. The transfer does not extinguish the underlying infringement allegations, and the company will need to respond to the complaint once properly served under case 25-cv-14255. The venue change may, however, affect local rules, judicial assignment, and procedural timelines — factors that can influence litigation strategy for the defense as it prepares its response.
Same exposure, new docketCannabis topical IP enforcement signals a maturing patent landscape
The willingness to file infringement actions over cannabis-derived botanical topical treatments suggests patent holders in this space are moving from portfolio-building to active enforcement. US10653736B2 covers a commercially relevant product category. Companies developing or distributing topical cannabis formulations should treat this filing — regardless of the procedural hiccup — as a signal that freedom-to-operate analysis in this category is increasingly urgent.
Cannabis topical IP enforcement risingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Metronome, LLC | Company | Cannabis-derived topical therapeutics IP holder — holder of US10653736B2Search in Eureka ↗ |
| Defendant | Bioserene, Inc. | Company | Bioserene, Inc. — defendant in cannabis topical treatment patent infringement actionSearch in Eureka ↗ |
| Plaintiff counsel | Terry Marcus Sanks | Attorney | Counsel for Metronome, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Beusse Sanks PLLC | Law Firm | Representing Metronome, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Florida Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The clerk’s notice reflects a purely administrative action — no judicial officer reviewed the merits and no legal standard was applied to the parties’ claims or defenses. The original docket was closed solely because the filer selected an incorrect venue in the electronic filing system. The substantive infringement dispute under US10653736B2 is unresolved and continues under renumbered case 25-cv-14255. Neither party’s legal position was altered by this procedural correction.
US10653736B2 — Cannabis-Derived Botanical Topical Drug Product
US10653736B2, filed under application number US16/257389, protects formulations and methods relating to topical treatments that incorporate cannabis species-derived botanical drug products. The patent sits at the intersection of botanical drug regulation and cannabinoid therapeutics — an area subject to evolving FDA guidance on botanical drug substances. The application date context suggests the patent was prosecuted during a period of rapid growth in cannabis IP filings, making claim scope and prosecution history particularly relevant to any validity or infringement analysis.
For the cannabis topical sector, this patent represents a meaningful IP asset. Topical cannabinoid formulations — including creams, balms, and transdermal patches — constitute a substantial and growing commercial category. Any competitor developing products in this space risks overlap with the claims of US10653736B2. The fact that Metronome has moved to litigation suggests the patent holder views its claims as commercially valuable and defensible. Competitors and licensees alike should treat this patent as a live enforcement risk.
Should you run an FTO analysis against US10653736B2?
Any company formulating, manufacturing, or distributing topical products derived from cannabis or hemp botanical extracts should assess their exposure to US10653736B2 before market entry or product expansion. This is particularly urgent for brands launching CBD or full-spectrum topical lines in the United States, given that Metronome has now demonstrated a willingness to pursue infringement litigation. The claims’ scope — covering botanical drug product incorporation in topical formats — may extend broadly across common product categories.
PatSnap Eureka’s FTO Search Agent allows R&D and product teams to map their formulation parameters against the granted claims of US10653736B2 in minutes. Eureka can identify overlapping claim language, surface related family members and continuations, and flag prior art that may inform design-around strategies or validity challenges — providing a defensible FTO opinion foundation before your product reaches market.
Run a freedom-to-operate analysis on US10653736B2 to assess your product’s exposure
Run FTO in Eureka →Similar cannabis botanical drug patent cases in U.S. federal courts
Explore related patent infringement actions involving cannabis-derived and botanical drug product formulations filed in U.S. District Courts.
What this case signals for the cannabis therapeutics IP landscape
A same-day transfer does not diminish the enforcement signal. Topical cannabis patent litigation is entering an active phase.
Cannabis botanical topical patents are now being actively enforced
The filing of this case — even with an immediate procedural correction — confirms that holders of cannabis-derived topical treatment patents are prepared to litigate. Product teams developing hemp or cannabis topical formulations should prioritise FTO clearance against US10653736B2 and related continuations before commercialisation.
Venue errors can delay but not defeat patent enforcement campaigns
The same-day administrative transfer demonstrates how quickly federal clerks act on venue selection errors. For defendants, this is a reminder that a misfiled case is not a procedural windfall — claims are preserved and litigation resumes under the corrected docket with no gap in enforceability.
Metronome v Bioserene — key questions answered
The case was administratively closed on the same day it was filed, July 16, 2025. The court clerk issued a notice that the filer had selected the wrong venue in the electronic filing system. The case was renumbered as 25-cv-14255, where the infringement action continues. No merits rulings were made on the original docket.
US10653736B2 covers topical treatments incorporating cannabis sp. derived botanical drug products. Filed under application US16/257389, it protects formulations at the intersection of cannabinoid therapeutics and botanical drug product regulation — a commercially significant category encompassing CBD creams, balms, and related topical formats.
No. An administrative closure due to a wrong venue selection does not extinguish or affect the underlying patent infringement claims. The allegations under US10653736B2 carry forward to the renumbered case 25-cv-14255. No rights were waived, and no dismissal — with or without prejudice — was entered.
Following the administrative closure of 1:25-cv-23170, the case was renumbered as 25-cv-14255. That docket is where the substantive patent infringement litigation over US10653736B2 is expected to proceed. No further entries will be made on the original case number.
Metronome LLC is represented by Beusse Sanks PLLC, with attorney Terry Marcus Sanks listed as plaintiff’s agent. The firm specialises in intellectual property matters. No defendant law firm or agent is recorded on the public docket at the time of administrative closure.
PatSnap Eureka searches patents and litigation data to answer instantly.